MAXIDEX 0.1 %
DEXAMETHASONE : 0.1 % · DIN 00042560 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is MAXIDEX?
MAXIDEX 0.1 % contains DEXAMETHASONE : 0.1 %. It is listed in the Health Canada Drug Product Database under DIN 00042560, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SUSPENSION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 22-Feb-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00042560 |
|---|---|
| Brand name | MAXIDEX |
| Generic / active ingredient | DEXAMETHASONE : 0.1 % |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 0.1 % |
| Dosage form | SUSPENSION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01BA01 DEXAMETHASONE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Feb-2018 |
Is DEXAMETHASONE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by STERIMAX INC (Tier 3 shortage DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP" aria-label="Actual Tier 3 shortage DEXAMETHASONE SODIUM P), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code S01BA01 DEXAMETHASONE. 3 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MAXIDEX | 0.1 % | OINTMENT | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 00042579 |
| OZURDEX | 0.7 MG | IMPLANT | ABBVIE CORPORATION | MARKETED | DIN 02363445 |
| OCUDEX LIQ 0.1% | .1 % | LIQUID | HERDT ET CHARTON INC. | CANCELLED POST MARKET | DIN 01995022 |
Who else supplies DEXAMETHASONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DEXAMETHASONE appears in 2222 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.